Lannett On Track To Launch Insulin Glargine By 2023

Company Expects Pivotal Trial For Lantus Biosimilar To Start In 2022

 
• By Akriti Seth
  
feedback
Lannett receives positive feedback from FDA for its biosimilar insulin glargine • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products